AMSTERDAM (MedPage Today) -- Survival in recurrent ovarian cancer increased significantly in patients who received a targeted agent with chemotherapy and as maintenance therapy, results of a randomized trial showed. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment